文献速递泌尿男性生殖肿瘤

美国食品药品监督管理局批准摘要:他拉唑帕利联合恩扎卢胺治疗同源重组修复基因突变转移性去势抵抗性前列腺癌患者

US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer.
PubMed 文献 · J Clin Oncol · 2024-03-07

美国食品药品监督管理局(FDA)基于TALAPRO-2随机双盲试验中同源重组修复基因突变(HRRm)人群批准他拉唑帕利联合恩扎卢胺用于HRRm转移性去势抵抗性前列腺癌(mCRPC)一线治疗。联合组较安慰剂组影像学无进展生存期(rPFS)显著改善,HRRm合并人群风险比(HR)为0.45(95%CI 0.33至0.61,P<.0001)。总生存期(OS)数据尚不成熟。

要点

  • FDA批准他拉唑帕利联合恩扎卢胺用于HRRm mCRPC一线治疗。
  • HRRm合并人群rPFS的HR为0.45(95%CI 0.33至0.61,P<.0001)。
  • 全人群rPFS虽显著改善,但FDA认为其幅度在广泛适应证下无临床意义。

核心结论

  • 尽管全人群队列rPFS有统计学显著改善,但结合广泛适应证、联合治疗及安全性特征,FDA认为该改善幅度无临床意义,故批准限于HRRm mCRPC患者。
  • HRRm mCRPC患者中rPFS有统计学显著且临床有意义的改善,OS结果有利,这是HRRm mCRPC一线治疗的首个批准。

研究设计与样本

  • 基于TALAPRO-2随机双盲试验的HRRm人群,该试验随机分配1035例mCRPC患者接受恩扎卢胺联合他拉唑帕利或安慰剂。
  • 试验序贯入组两个队列:全人群队列(队列1),随后为仅HRRm人群(队列2)。
  • 独立主要终点为盲法独立中心审查(BICR)评估的队列1(全人群)及HRRm合并人群(队列1和2中所有HRRm患者)的rPFS;OS为关键次要终点。

主要发现

  • 全人群队列rPFS的HR为0.63(95%CI 0.51至0.78,P<.0001)。
  • HRRm合并人群rPFS的HR为0.45(95%CI 0.33至0.61,P<.0001)。
  • 155例BRCA突变mCRPC患者的探索性分析中,rPFS的HR为0.20(95%CI 0.11至0.36)。
  • 队列1非HRRm/未知分层(n=636)中rPFS的HR为0.70(95%CI 0.54至0.89)。
  • OS数据尚不成熟。

关键数值与推荐

  • FDA批准他拉唑帕利联合恩扎卢胺用于HRRm mCRPC一线治疗。
  • 批准基于HRRm合并人群rPFS的HR 0.45(95%CI 0.33至0.61,P<.0001)。

临床怎么用

  • 他拉唑帕利联合恩扎卢胺可用于HRRm mCRPC患者的一线治疗。
  • 全人群mCRPC患者中不推荐该联合方案用于广泛适应证。

局限性

  • OS数据尚不成熟。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The US Food and Drug Administration (FDA) approved talazoparib with enzalutamide for first-line treatment of patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC). PATIENTS AND METHODS: The approval was based on the HRR gene-mutated (HRRm) population of TALAPRO-2, a randomized, double-blind trial that randomly assigned 1,035 patients with mCRPC to receive enzalutamide with either talazoparib or placebo. Two cohorts enrolled sequentially: an all-comer population (Cohort 1), followed by an HRRm-only population (Cohort 2). The independent primary end points were radiographic progression-free survival (rPFS) per blinded independent central review (BICR) in Cohort 1 (all-comers) and in the combined HRRm population (all HRRm patients from Cohorts 1 and 2). Overall survival (OS) was a key secondary end point. RESULTS: A statistically significant improvement in rPFS by BICR was demonstrated in both the all-comers cohort and the combined HRRm population, with hazard ratio (HR) of 0.63 (95% CI, 0.51 to 0.78; P < .0001) and 0.45 (95% CI, 0.33 to 0.61; P < .0001), respectively. In an exploratory analysis of the 155 patients with BRCA-mutated (BRCAm) mCRPC, rPFS HR was 0.20 (95% CI, 0.11 to 0.36). In the non-HRRm/unknown stratum of Cohort 1 (n = 636), the rPFS HR was 0.70 (95% CI, 0.54 to 0.89). OS was immature. CONCLUSION: Despite a statistically significant rPFS improvement in the all-comer cohort, FDA did not consider the magnitude of rPFS clinically meaningful in the context of the broad indication, combination treatment, and safety profile. Approval was therefore limited to patients with HRRm mCRPC, for whom there was a statistically significant and clinically meaningful improvement in rPFS and favorable OS results. This represents the first approval for the first-line treatment of patients with HRRm mCRPC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Heiss BL, Chang E, Gao X, et al. US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2024. PMID: 38452327. doi:10.1200/JCO.23.02182

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。